Identification of Biomarkers for Early Detection of Pancreatic Cancer
| Status: | Completed |
|---|---|
| Conditions: | Cancer, Cancer, Pancreatic Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 120 |
| Updated: | 4/21/2016 |
| Start Date: | February 2005 |
| End Date: | April 2011 |
Michigan Center for Pancreatic Cancer Molecular Diagnosis: The Serum Protein Microarray Project
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help
doctors learn more about changes that may occur in DNA and identify biomarkers related to
cancer.
PURPOSE: This laboratory study is examining blood samples from patients with cancer to
identify biomarkers that may help in the early detection of pancreatic cancer.
doctors learn more about changes that may occur in DNA and identify biomarkers related to
cancer.
PURPOSE: This laboratory study is examining blood samples from patients with cancer to
identify biomarkers that may help in the early detection of pancreatic cancer.
OBJECTIVES:
- Identify specific proteins of interest to evaluate for their potential role as markers
for pancreatic cancer.
- Analyze serum proteins directly by mass spectrometry to identify new biomarkers of
pancreatic cancer that can be used for early diagnosis.
OUTLINE: Blood from patients is collected prior to treatment. Plasma proteins are analyzed
by matrix-assisted laser desorption ionization time-of-flight mass spectrometry
(MALDI-TOF/MS) and/or electrospray mass spectrometry (ESI/MS).
PROJECTED ACCRUAL: A total of 120 patients will be accrued for this study.
- Identify specific proteins of interest to evaluate for their potential role as markers
for pancreatic cancer.
- Analyze serum proteins directly by mass spectrometry to identify new biomarkers of
pancreatic cancer that can be used for early diagnosis.
OUTLINE: Blood from patients is collected prior to treatment. Plasma proteins are analyzed
by matrix-assisted laser desorption ionization time-of-flight mass spectrometry
(MALDI-TOF/MS) and/or electrospray mass spectrometry (ESI/MS).
PROJECTED ACCRUAL: A total of 120 patients will be accrued for this study.
DISEASE CHARACTERISTICS:
- Diagnosis of pancreatic cancer
- Newly diagnosed disease
- Planning to undergo surgery or other treatment for pancreatic cancer at Karmanos
Cancer Institute or its affiliates
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
We found this trial at
1
site
Barbara Ann Karmanos Cancer Institute Karmanos is based in southeast Michigan, in midtown Detroit, and...
Click here to add this to my saved trials
